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Antibiotic-resistant bacteria are becoming a serious threat to public health worldwide. To address this
problem, we have developed multifunctional peptide (MFP)-coated silver nanoparticles (MFP@AgNPs) for
antibacterial studies. MFPs, which can physically adsorb to AgNPs via electrostatic interactions are
comprised of a matrix metalloproteinase (MMP) cleavable sequence (PVGLIG), an antimicrobial peptide
(tachyplesin-1), and a target peptide (PGP-PEG). The resulting MFP@AgNPs were characterized by
various technologies, including UV-vis spectrophotometry, zeta potential analyzer, circular dichroism
(CD) spectroscopy, attenuated total reflection-Fourier-transform infrared spectroscopy (ATR-FTIR), and
transmission electron microscopy (TEM). The MIC and MBC were investigated against both Gram-
positive bacteria and Gram-negative bacteria. The antibacterial activity in vivo was evaluated on MDR-AB
(multidrug-resistant Acinetobacter baumannii) infected mice. We found that MFP@AgNPs exhibited
antibacterial activity against both Gram-positive bacteria and Gram-negative bacteria. Compared to bare
AgNPs, MFP@AgNPs-1 killed MDR-AB faster and more efficiently. SEM images showed that MFP@AgNPs-
1 induced cell disruption via cell membrane damage. In vivo studies further confirmed the enhanced
antibacterial activity against MDR-AB infections. The developed MFP@AgNPs-1 reduced the cytotoxicity
of AgNPs and enhanced the antibacterial activity against MDR-AB in vitro and in vivo, providing
a possible solution against multidrug-resistant bacterial infections.1. Introduction
Antibiotic-resistant bacteria are becoming a serious threat to
public health worldwide.1,2 The infections caused by these
bacteria are difficult to be cured by antibiotics that used to be
efficacious. Solutions to this problem include controlling anti-
biotic use, developing new antibiotics and inhibiting evolu-
tion.3,4 With the development of nanotechnology, nanoparticles
have drawn much attention in the antibacterial eld and are
promising as alternatives to new antibiotics. ZnO particles,5,6
chitosan nanoparticles,7,8 silver nanoparticles (AgNPs),9,10 gra-
phene,11 and some composite particles12,13 have been synthe-
sized and used for antibacterial studies. Among these particles,u University, Zhengzhou, Henan 450001,
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e work.
38754AgNPs have been intensively studied because of their excellent
antibacterial activity.14 However, their applications are limited
due to the poor activity against drug-resistant pathogens and
their toxicity.14,15 To reduce toxicity, one possible solution is to
modify the AgNPs surface with different biomolecules via
covalent or non-covalent approaches.16
Antimicrobial peptides (AMPs) are natural peptides that
exhibit strong antibacterial activities.17 AMPs are usually posi-
tively charged and can interact with microbial membranes
through electrostatic interactions, resulting in morphology
damage.18 To increase the efficacy, AMPs are generally modied
by adding some fragments. N-Acetylated Proline–Glycine–
Proline (N-ac-PGP) is chemotactic for neutrophils in vitro as well
as in vivo.19 N-ac-PGP exerts its chemotactic activity by
mimicking key sequences found within classical neutrophil
chemokines (such as CXCL8) and targets its receptor CXCR1/2
to alleviate chronic neutrophilic lung diseases.20 Matrix metal-
loproteases (MMPs), especially MMP2, are overexpressed in
some types of human inammation microenvironments.21
PVGLIG is an MMP-2-sensitive peptide and has been success-
fully modied on nanoparticle surfaces for targeted drug
delivery systems.22,23 It is reported that tachyplesin-1 peptide is
an AMP with a b-hairpin structure, and can induce cell
apoptosis via a membranolytic mechanism;24,25 however, it is
strongly hemolytic against mammalian erythrocytes,26 and alsoThis journal is © The Royal Society of Chemistry 2020
Scheme 1 Schematic illustration of (A) the multifunctional peptide (MFP) design, (B) the preparation of MFP@AgNPs and (C) the possible


































































































View Article Onlineshows the disadvantages of poor stability and membrane
penetration.27 To improve these drawbacks of tachyplesin-1 and
reduce the cytotoxicity of AgNPs, we developed multifunctional
peptide (MFP)-coated AgNPs (MFP@AgNPs) for antibacterial
studies. The MFP is comprised of an MMP cleavable sequence
(PVGLIG), an AMP (tachyplesin-1) and a target peptide (N-ac-
PGP-PEG) (Scheme 1). PEGylation can enhance the circulation
of AgNPs in vivo while it shields the targeting properties of
ligands by weakening the intracellular trafficking of cellular
uptake and endosomal escape.28 Together with PGP-PEG,
PVGLIG can prevent tachyplesin-1 from degradation by
enzymes and prolong its bioactivity. Once arriving at the slightly
acidic (pH < 6.5) infection microenvironment, MFP can disas-
sociate so that PVGLIG is cleaved by MMP, resulting in the
exposure of tachyplesin-1 and further bioactivities.
MFP@AgNPs were prepared by mixing the positively charged
MFPs and the negatively charged AgNPs. The antibacterial
activity of MFP@AgNPs was rst investigated against both
Gram-positive bacteria and Gram-negative bacteria, followed by
in vivo studies on MDR-AB-infected mice. Our results suggest
that surface modication with MFP enhanced the antibacterial
activity of AgNPs against MDR-AB, providing a new solution to
anti-MDR studies.2. Materials and methods
2.1 Materials
The tachyplesin-1 and MFP were synthesized by DGP Peptides
Co. Ltd. (Hangzhou, China). Silver nanoparticles with an
average size of 20 nm were purchased from Zhongke Leiming
Co. Ltd. (Beijing, China). Ultrapure Milli-Q water (18 MU cm;
Millipore-Q; EMD Millipore, Billerica, MA, USA) was used for
solution preparation. The CCK-8 kit was purchased from
Dojindo (Japan). TNF-a and IL-6 Elisa kits were purchased from
Ikesai Biotechnology (Taicang, China). Amikacin was provided
by Bidepharm (Shanghai, China). Propidium iodide (PI) andThis journal is © The Royal Society of Chemistry 20202.5% glutaraldehyde were obtained from Legend Biotech (Bei-
jing, China). The hematoxylin-eosin staining kit, vancomycin
and phosphate-buffered solution were bought from Solarbio®
Life Sciences (Beijing, China). Cyclophosphamide was
purchased from Ryon Biological Technology (Shanghai, China).
Mueller-Hinton broth (MHB) and Mueller–Hinton agar (MHA)
were obtained from Aobox (Beijing, China). Acinetobacter
chromogenic agar was provided by CHROMagar (Paris, France).
Sheep red blood cells were purchased from Bianzhen Biotech
(Nanjing, China). Saline solution was obtained from Kelun
Pharmaceutical Co. (Henan, China). All the above-mentioned
materials were used without any further modication.
E. coli (Escherichia coli), MDR-AB (multidrug-resistant Acine-
tobacter baumannii bacteria), S. aureus (Staphylococcus aureus)
and MRSA (Methicillin-resistant Staphylococcus aureus) were
provided by Dr Shangshang Qin (Zhengzhou University, Henan,
China). Female BALB/c mice were obtained from the laboratory
animal center of Henan province [license number: SCXK (Yu)
2017-0001]. Animal care and experiments were carried out with
the approval of the Animal Ethics Committee of Zhengzhou
University (Zhengzhou, China) according to the requirements of
the National Act on the Use of Experimental Animals (China).
2.2 Preparation of MFP@AgNPs conjugates
AgNPs (nal concentration: 64 mg mL1, nal volume: 1 mL)
were incubated with MFP at different mass ratios (1 : 0.5, 1 : 1,
and 1 : 1.5) in the dark at 37 C. Aer 12 h, the particles were
collected by centrifugation (10 000 rpm, 30 min) and washed
twice with water. The resulting particles were redispersed in
1 mL of water and denoted as MFP@AgNPs-0.5, MFP@AgNPs-1,
and MFP@AgNPs-1.5, respectively. All the supernatants were
collected and quantied by UV-vis spectroscopy (UV-2700, Shi-
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2.3 UV-vis spectroscopy
AgNPs, MFP and MFP@AgNPs were diluted with water and the
UV-vis absorbance of the samples was recorded via UV-vis
spectroscopy (UV-2700, Shimadzu, China).
2.4 Zeta potential analysis
AgNPs and MFP@AgNPs were diluted with water followed by
zeta potential analysis using a zeta potential analyzer (NGL-
88Bano, Malvern, UK).
2.5 Circular dichroism (CD) spectroscopy
The secondary structure of MFP on AgNPs was conrmed by CD
spectroscopy (J-1500, JASCO, Japan). The samples were loaded
into the cuvette (Hellma Analytics, Munich, Germany) with
a light path of 1 mm and scanned from 190 to 260 nm with
a resolution of 1 nm.
2.6 Attenuated total reection-Fourier-transform infrared
spectroscopy (ATR-FTIR)
The infrared spectra of MFP@AgNPs were recorded by ATR-
FTIR (6700, Nicolet, USA). For each sample, an accumulation
of 100 interferograms was collected in single beam mode from
4000 cm1 to 400 cm1 with a resolution of 4 cm1.
2.7 Transmission electron microscopy (TEM)
The morphologies of AgNPs and MFP@AgNPs were determined
by TEM (HT7700, Philips-FEI, Netherlands). Here, 10 mL of the
sample was spotted on a discharged TEM grid and incubated for
20 s. Aer the removal of the excess sample, the grid was
puried with 50 mL of water followed by staining with 2% of
aqueous uranyl formate solution. Aer 30 s, the excess solution
was removed by lter paper. The grid was dried at room
temperature and prepared for TEM imaging.
2.8 Cell culture
Both Gram-positive bacteria (S. aureus and MRSA) and Gram-
negative bacteria (E. coli and MDR-AB) were used for in vitro
antibacterial activity studies. All the bacteria were cultured in
Nutrient broth at 37 C on a shaker (200 rpm) or agar plates at
37 C without shaking.
2.9 Minimum inhibitory concentration test (MIC)
The MIC of MFP@AgNPs, AgNPs, MFP, and tachyplesin-1 were
determined by the broth micro-dilution method.29 Briey, E.
coli, MDR-AB, S. aureus and MRSA were seeded in 96 well plates
at a density of 5  103 CFU per well (1  105 CFU mL1, 50 mL).
Various concentrations (from 64 to 0.125 mg mL1, 50 mL) of
MFP@AgNPs, MFP, and AgNPs in MHB medium were added to38748 | RSC Adv., 2020, 10, 38746–38754each well. Amikacin and vancomycin were used as positive
controls for the treatment of Gram-negative bacteria and Gram-
positive bacteria, respectively. Bacteria without any treatment
were used as negative controls. All the experiments were per-
formed in triplicate. The bacteria were incubated under stan-
dard conditions for 16–20 h. The optical density at 600 nm was
measured using a microplate reader (Powerwave XS2, BioTek,
USA).
2.10 Time-dependent killing
Time-dependent killing was performed according to the
previous study.30 A single colony of MDR-AB was pre-cultured in
MHB medium for 12 h at 37 C in a shaker (200 rpm). The pre-
culture was diluted 10 000 times with MHB medium and ali-
quoted at 1.5 mL per tube. Aer incubation for 2 h, the bacteria
were treated with MFP@AgNPs-1, AgNPs, MFP, and tachyplesin-
1 at different concentrations (1 MIC, 3 MIC, and 6 MIC).
Amikacin-treated bacteria were used as positive controls.
Bacteria without any treatment were used as negative controls.
Then, 100 mL of bacteria were collected at different time points
(0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 24 h) and centrifugated at
4000 rpm for 3 min. The bacteria were redispersed in 1 mL of
PBS and 10 mL of the resulting samples were seeded on an MHA
plate and cultured at 37 C overnight. Colonies were counted
and the living bacteria in each sample were calculated.
2.11 Morphological characterization
Scanning electron microscopy (SEM) was used to investigate the
morphological changes of MDR-AB that were treated with
MFP@AgNPs-1, AgNPs, MFP, and tachyplesin-1 at 3 MIC. A
single colony of MDR-AB cells was seeded in 1 mL of MHB
medium and cultured under standard conditions for 5 h. Aer
incubation, the bacteria were collected by centrifugation
(4000 rpm, 10 min) and redispersed in 5 mL of PBS. The
bacteria were aliquoted and treated with MFP@AgNPs-1,
AgNPs, MFP, and tachyplesin-1, amikacin and MHB medium,
respectively. Aer incubation for 30 min, the bacteria were
collected by centrifugation (8000 rpm, 1 min) and washed three
times with PBS. The bacteria were xed with 2.5% glutaralde-
hyde at 4 C overnight and dehydrated with various concen-
trations of ethanol (from 30% to 100%, incubation time: 15
min).31 To remove any moisture, the bacteria were further
dehydrated in ethanol/tert-butanol (v/v, 50%) and tert-butanol
(100%) for 15 min, respectively. The resulting samples were
spotted on a monocrystalline silicon wafer and dried under
vacuum at 37 C followed by SEM imaging.
2.12 Antibacterial mechanism
Propidium iodide (PI) was utilized to investigate the integrity of
the cell membrane32. Bacteria were seeded in a black 96 well
plate at a nal concentration of 1.5  107 CFU per well. PI
(10 mM, 50 mL) was added to each well and incubated under
standard conditions for 30 min. Before treatment, the uores-
cence intensity at 617 nm was determined every 2 min with
a microplate reader (EnSpire, PerkinElmer, USA) using an


































































































View Article Onlinetachyplesin-1, and amikacin were added. For the negative
control, the same volume of water was added. The uorescence
intensity of each well was measured every 2 min using the same
method.
2.13 Cytotoxicity in vitro
The cytotoxicity of the developed materials was tested against
the human umbilical vein endothelial cells (HUVEC) via CCK8
assay. HUVEC were seeded in a 96 well plate at a nal density of
5  103 cells per well and cultured under standard conditions
(37 C, 5% CO2, humidity 100%) for 24 h. The digested medium
was replaced with fresh medium containing MFP@AgNPs-1,
AgNPs, and MFP (concentration various from 256 to
8 mg mL1). Aer incubation for 24 h, the medium was removed
and the cells were washed with PBS once. The cells were incu-
bated with 100 mL of fresh medium containing 5% of CCK8
agent for 4 h followed by absorbance measurements with the
microplate reader. The cytotoxicity was calculated by the
following equation:
Cellular viability ð%Þ ¼ ODcontrol ODdrug
ODcontrol ODblank  100
2.14 Hemolysis
Sheep red blood cells were used as model blood cells to evaluate
the biocompatibility of MFP@AgNPs-1. Here, 2 mL of sheep
blood were washed with PBS at least three times and redis-
persed in 20 mL of PBS to obtain 10% of blood cells. Various
concentrations (from 256 to 8 mg mL1) of MFP@AgNPs-1 were
incubated with the same volume of 10% blood cells for at 37 C
for 1 h. Then, 0.1% of Triton X-100 treated blood cells were used
as positive controls. Aer incubation, the cells were collected by
centrifugation (1000 rpm, 15 min). The UV-vis absorbance at
540 nm of the samples' supernatant (150 mL) was determined by
the microplate reader. The hemolysis rate was calculated via the
following equation:
H ð%Þ ¼ A1  A0
Atotal  A0  100
where A1 is the OD of the sample, A0 is the OD of the negative
control, and Atotal is the OD of the positive control.
2.15 Antibacterial activity in vivo
MDR-AB-infected female BALB/c mice were used as pneumonia
models for the antibacterial activity study of MFP@AgNPs-1 in
vivo. The models were constructed according to the previous
study.33 Here, 36 of MDR-AB-infected mice were divided into 6
groups and treated with MFP@AgNPs-1, AgNPs, MFP,
tachyplesin-1, amikacin, and PBS for three days at a dosage of
0.1 mg per kg per day by intravenous injection, respectively. Six
healthy mice were used as negative controls. The weights and
temperatures of the mice were recorded every day.
Aer three days' treatment, the blood of each mouse was
collected via retro-orbital bleeding. The neutrophil-to-
lymphocyte ratio (NLR) and neutrophils (NEUT) were deter-
mined by an automatic animal blood analyzer (XT-2000iv,This journal is © The Royal Society of Chemistry 2020SYSMEX, Japan).34,35 The right-upper lungs were removed from
the bodies and washed with PBS. The weight of the lungs was
recorded before and aer drying. The weight ratio was calcu-
lated by the following equation:
Lung weight ratio ð%Þ ¼ mdry
mwet
 100
The distribution of bacteria in each organ of the mouse was
also investigated. The hearts, livers, spleens, lungs, and kidneys
were removed from the mouse bodies, washed with sterile
saline solution and dried with lter paper, followed by
homogenizing in ice-cold saline solution (9 mL g1). The
resulting homogenate of each organ was cultured on an acine-
tobacter chromogenic agar plate (CHOMagar, Paris, France) at
37 C overnight. The colonies were counted and the density of
the bacteria in each organ was calculated. The inammatory
factors, TNF-a and IL-6, in the lung tissue homogenate were
determined via enzyme-linked immunosorbent assay (ELISA)
using TNF-a ELISA kits and IL-6 ELISA kits, respectively. The
experiments were carried out following the manual instructions
without any modications. For the histopathological study, the
le lung of each mouse was stained by hematoxylin–eosin (HE)
and imaged with optical microscopy. The lung tissue sections
were prepared by the same method as the previous study.36 In
brief, lungs were xed in formalin (pH 7.0) overnight and
embedded in paraffin, followed by HE staining. The HE stained
lung sections were imaged with optical microscopy (Leica Bio-
systems Imaging Inc., GER) and the results were generated by
Image Scope Soware (Leica Biosystems Imaging Inc).
2.16 Statistical analysis
Statistical analysis was performed using SPSS 21.0. All experi-
ments were repeated at least three times, the data are presented
as mean  SD. One-way analysis of variance (ANOVA) was used
to compare to differences among three or more groups (statis-
tical signicance: p < 0.05).
3. Results and discussion
3.1 Preparation and characterization of MFP@AgNPs
conjugates
To prepare MFP@AgNPs conjugates, we incubated MFP with
AgNPs at different mass ratios. The mass ratio and loading
capacity are listed in Table 1. The loading capacity increased
with the increase in the mass ratio.
We then used different technologies, including UV-vis
spectroscopy, zeta potential analyzer, ATR-FTIR (attenuated
total reection-Fourier-transform infrared spectroscopy), CD
(circular dichroism) spectroscopy and TEM (transmission elec-
tron microscopy), to characterize the resulting MFP@AgNPs
conjugates (Fig. 1). It is well-known that AgNPs show UV-vis
absorption in the range of 400–500 nm because of strong
surface plasmon resonance (SPR).37 The changes in the UV-vis
absorption can be used to monitor the particle surface reac-
tions.38,39 As shown in Fig. 1A, MFP@AgNPs conjugates exhibi-
ted the specic absorption of MFP at 280 nm and AgNPs atRSC Adv., 2020, 10, 38746–38754 | 38749
Table 1 The concentrations of MFP and AgNPs used for the preparation of MFP@AgNPs, and the loading capacity
Name Mass ratio MFP/AgNPs
Concentration (mg mL1) Loading capacity
MFP AgNPs (mg mL1)a (mg mg1)b
FP@AgNPs-0.5 0.5 32 64 0.94 0.063
MFP@AgNPs-1 1 64 64 5.5 0.177
MFP@AgNPs-1.5 1.5 96 64 7.95 0.273
a Loading capacity ðmg mL1Þ ¼ madded msupernatant
V
: b Loading capacity ðmg mg1Þ ¼ madded msupernatant
mAgNPs
:
Fig. 1 Characterization of MFP@AgNPs conjugates. (A) UV-vis spectra, (B) zeta potential, (C) ATR-FTIR spectra, (D) CD spectra of AgNP, MFP and


































































































View Article Online410 nm. Furthermore, we observed a decrease in intensity at
410 nm and a redshi to 587 nm, in agreement with the
previous study.40 With the surface coating of MFP, the SPR
property of AgNPs decreased, resulting in a reduced absorbance
at 410 nm. The redshi to 587 nm indicated that the surface of
AgNPs changed due to MFP binding. The changes in UV-vis
absorption can be explained by the MFP shell on AgNPs,
which might affect the SPR. Compared to AgNPs, the zeta
potential of the MFP@AgNPs conjugates decreased due to the
positively charged MFP (theoretical isoelectric point: 10.1,
calculated by Geneious 9.1.3) under neutral conditions (Fig. 1B).38750 | RSC Adv., 2020, 10, 38746–38754Aer coating with MFP, the zeta potential of AgNPs shied from
8 mV to 4 mV (MFP@AgNP-0.5). With the increase in
MFP, the zeta potential further decreased to 0 mV
(MFP@AgNP-1). These results demonstrated that MFP was
successfully added to the particle surface. The ATR-FTIR spectra
of MFP@AgNPs conjugates exhibited variations in the Ag–O/Ag–
Ag (565 cm1 and 730 cm1)41,42 and stretching variations of
C]O (1650 cm1) and bending variations of N–H (1540 cm1
and 1515 cm1)43 (Fig. 1C). CD spectroscopy is oen used to
investigate the secondary structures of peptides and proteins.
As shown in Fig. 1D, the MFP and different MFP@AgNPsThis journal is © The Royal Society of Chemistry 2020
Table 2 MIC and MBC of different items against Gram-positive bacteria and Gram-negative bacteriaa
Items
MIC* (mg mL1) MBC* (mg mL1)
S. aureus MRSA E. coli MDR-AB
S.
aureus MRSA E. coli MDR-AB
Amikacin N.A. N.A. 2 1 N.A. N.A. 2 1
Vancomycin 2 2 N.A. N.A. 2 2 N.A. N.A.
AgNPs 2 2 16 32 2 8 16 32
Tachyplesin-1 16 2 0.125 1 16 2 0.125 1
MFP 4 16 2 4 16 16 2 4
MFP@AgNPs-0.5 16 16 8 8 16 16 8 8
MFP@AgNPs-1 8 16 2 2 16 16 8 4
MFP@AgNPs-1.5 8 16 4 2 16 16 4 2


































































































View Article Onlineconjugates exhibited negative ellipticity with a signicant peak
in the range of 190–215 nm, which represents the random coil
structure.44 These results demonstrate that the secondary
structure of MFP was retained aer conjugation to AgNPs. TEM
images showed the spherical morphology of AgNPs and
MFP@AgNPs-1 with an average size of 21.7 2.5 nm and 25.7
5.6 nm, respectively (Fig. 1E).3.2 In vitro antibacterial activity
The antibacterial activity in vitro of MFP@AgNPs was investi-
gated against Gram-positive bacteria (S. aureus and MRSA) and
Gram-negative bacteria (E. coli and MDR-AB). We tested both
the MIC (minimum inhibitory concentration) and the MBCFig. 2 Time-kill efficacy and antibacterial mechanism against MDR-AB.
changes after treatment. (D) The integrity of the cell membrane by mon
This journal is © The Royal Society of Chemistry 2020(minimum bactericidal concentration). The results are listed in
Table 2. In agreement with previous studies,45,46 AgNPs had an
effect on both Gram-positive bacteria and Gram-negative
bacteria. However, AgNPs were more effective towards Gram-
positive bacteria than Gram-negative bacteria. The antibacte-
rial peptide tachyplesin-1 and MFP were able to inhibit and kill
E. coli, and MDR-AB at lower concentrations. Compared to MFP
and AgNPs, MFP@AgNPs conjugates exhibited stronger anti-
bacterial activity towards Gram-negative bacteria and overcame
the drug resistance of AgNPs against MDR-AB. The antibacterial
activity of MFP@AgNPs-1 against MDR-AB was almost equiva-
lent to the positive control amikacin. Considering the cost of
the experiments, MFP@AgNPs-1 was used for further studies.
To better understand the antibacterial activity of MFP@AgNPs-1Time-kill kinetic assay at (A) 3 MIC and (B) 6 MIC. (C) Morphology
itoring the fluorescence intensity of PI overtime.


































































































View Article Onlineagainst MDR-AB, we investigated the time-kill kinetics at 3
MIC and 6 MIC (Fig. S1†).
As shown in Fig. 2A, MFP@AgNPs-1 exhibited the greatest
kill efficacy at 3MIC. MFP@AgNPs-1 could kill 99.9% of MDR-
AB within 0.5 h, which wasmuch faster than the positive control
amikacin. On the contrary, the other groups were not able to
effectively kill MDR-AB within 24 h. When the concentration
was increased to 6MIC, MFP@AgNPs-1, MFP and tachyplesin-
1 showed very similar kill efficacies (Fig. 2B). They killed MDR-Fig. 3 Antibacterial activity in vivo. (A) Bacterial distribution in the liver, lun
the histological analysis of the lung tissues. (E) Levels of IL-6 in lung h
assessment.
38752 | RSC Adv., 2020, 10, 38746–38754AB within 0.5 h, while AgNPs took 2 h. We further used SEM to
observe the morphology of MDR-AB. As shown in Fig. 2C, MFP,
tachyplesin-1 and AgNPs slightly affected the cell morphology.
However, MFP@AgNPs-1 completely destroyed the morphology
of MDR-AB, which was even stronger than the positive control
amikacin. These results were further conrmed by monitoring
the uorescence intensity of MDR-AB using PI (propidium
iodide) staining. Eight minutes later, bacteria (MDR-AB and PI
mixture) were treated with AgNPs, MFP, tachyplesin-1,g and heart; (B) NLR; (C) number of NEUT. (D) Representative images of
omogenate. (F) Levels of TNF-ain lung homogenate, (G) lung edema


































































































View Article OnlineMFP@AgNPs-1 and amikacin, respectively. The results are
shown in Fig. 2D. Before treatment, the uorescence intensity of
each group showed no differences. Aer treatment, the uo-
rescence intensity increased signicantly in MFP@AgNPs-1 and
tachyplesin-1 groups. The increasing uorescence intensity
suggested that PI combined with DNA, indicating that the cell
wall and cell membrane of MDR-AB were destroyed. On the
contrary, the uorescence intensity only increased slightly in
the AgNPs andMFP groups. The constant uorescence intensity
in the amikacin group was attributed to the strong interaction
between amikacin and nuclear DNA, which weakened the
interaction between PI molecules and DNA molecules.47,483.3 In vivo antibacterial activity
We evaluated the antibacterial activity of MFP@AgNPs-1 in vivo
usingMDR-AB-infectedmice models. Before administration, we
conrmed the good biocompatibility of MFP@AgNPs-1 with
a cytotoxicity assay (Fig. S2†) and hemolysis assay (Fig. S3†). As
shown in Fig. S3,† the hemolytic rate of MFP@AgNPs-1
increased to 8% at the concentration of 256 mg mL1.
However, the therapeutic concentration of MFP@AgNPs-1 was
only 0.1 mg per kg per day (blood concentration: 20 mg mL1).
Therefore, the hemolysis assay was not determined at higher
concentrations. The infected mice were treated with PBS,
AgNPs, MFP, tachyplesin-1, MFP@AgNPs-1 and amikacin,
respectively. The treatment started on the h day and lasted
for 3 days. The weights of the mice decreased aer the treat-
ment with AgNPs, MFP, tachyplesin-1 and amikacin. The
constant weight and temperature of the mice in the
MFP@AgNPs-1 group indicated the good biocompatibility of
MFP@AgNPs-1 (Fig. S4†). Besides, 100% of mice survived aer
treatment with MFP@AgNPs-1 (Fig. S5†). To better understand
the antibacterial therapy, we executed all the mice and analyzed
MDR-AB distribution in blood and different organs aer treat-
ment. MDR-AB occurred in the liver, lungs and heart of the
infected mice (Fig. 3A). Aer treatment, the number of MDR-AB
signicantly decreased in these organs (AgNPs vs.MFP@AgNPs-
1, p < 0.001). The neutrophil-to-lymphocyte ratio (NLR) and
neutrophils (NEUT) are oen used to evaluate systemic
inammation and infection.49,50 Compared to the model group,
both NLR and NEUT increased aer therapy (Fig. 3B and C). The
numbers of NLR and NEUT in MFP@AgNPs-1 and amikacin
groups were equivalent to the control group, indicating the best
recovery of these mice.
We next investigated the morphology of the lung tissues. As
shown in Fig. 3D, MDR-AB-infected mice showed obvious
pathological changes with alveolar edema, swelling capillaries
and narrow bronchi.51 Aer therapy with MFP, tachyplesin-1
MFP@AgNPs-1 and amikacin, the structure of the lung tissues
improved with reduced inammation. However, inammatory
cell inltration was still observed in the AgNPs group (Fig. 3D).
Inammatory stimulus can increase the Interleukin-6 (IL-6)
concentrations and tumor necrosis factor-a (TNF-a).52 To
further evaluate the therapy of each group, we determined the
concentrations of IL-6 and TNF-a in lung tissues. As shown in
Fig. 3E and F, the concentrations of IL-6 and TNF-a decreasedThis journal is © The Royal Society of Chemistry 2020aer treatment, indicating reduced inammation. Compared to
the AgNPs group and MFP group, the MFP@AgNPs-1 group
showed better activity with anti-inammation therapy. Pulmo-
nary edema also improved aer the antibacterial therapy with
tachyplesin-1, MFP@AgNPs-1 and amikacin (Fig. 3G).
4. Conclusion
We have successfully developed a designed multifunctional
peptide-coated AgNPs for antibacterial study. The bioactivity of
the designed MFP was maintained aer binding to the particle
surface. Compared to the bare AgNPs, MFP@AgNPs exhibited
excellent antibacterial activity against MDR-AB, which was
further conrmed by the in vivo study on MDR-AB-infected
mice. The developed MFP@AgNPs provides a possible solu-
tion against multidrug-resistant bacterial infections.
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